Spike Protein Antibody vs Antigen Testing: What Each One Measures

If you've paid for a "spike protein level" test and come away with a number you can't interpret, this article is for you. The single most useful distinction in this whole field is between antibody and antigen, and most products blur it. By the end you'll know what your number measures, what it doesn't, and what a more complete assessment looks like.

Antibody vs antigen: the distinction that matters

Antigen means the spike protein itself. If circulating spike antigen is detected in your blood, that's direct evidence the protein is present.

Antibody means your immune system's response to spike: IgG, IgM, IgA. These are proteins your B cells made because spike was present at some point. They are not spike.

Nearly every commercially available "spike protein level" test measures anti-spike antibody, usually anti-S1 or anti-RBD IgG, on a standard immunoassay platform. Results come back in U/mL or BAU/mL precisely because they're calibrated against an antibody standard.

So a high antibody number tells you your immune system has been heavily stimulated by spike or something spike-like. It doesn't tell you how much spike antigen is in your body now, in which tissues, or in what form.

Why antibody titres move around

• Time since exposure. Antibodies decay over months and years.
• Re-exposure. Every infection, symptomatic or not, and every booster can push titres up sharply.
• Cross-reactivity. Broader coronavirus exposure can boost some assays.
• Class switching. Chronic stimulation can shift IgG subclasses and alter affinity.
• Assay choice. Anti-S1, anti-RBD, anti-N, total Ig, IgG-only, IgM, IgA all measure different things, and labs don't standardize.
• Underlying autoimmunity. Shifted polyclonal antibody activity can distort readings.

Clinical next step

Looking for more than a single antibody number?

Our at-home amyloid fibrin test adds one objective observation to the picture: what Thioflavin T microscopy sees in your blood.

Start screening

What direct antigen testing adds

Antigen detection is harder than antibody detection. It needs mass spectrometry workflows, careful sample handling, controls for matrix effects and validated reference standards. It costs considerably more, and almost no wellness brand offers it.

The published proof of concept came from Brogna and colleagues, who used mass spectrometry with the vaccine-specific proline mutation as a benchmark and detected the recombinant spike fragment in 50% of the biological samples they analyzed, between 69 and 187 days after vaccination, independent of antibody titre (Brogna et al., 2023).

That study is small and methodologically specialised. It establishes detection, not harm. But it shows the measurement is possible, and that antibody titre and antigen presence are genuinely different readouts.

Why spike might persist: three hypotheses

Tissue reservoir

The most clinically established hypothesis is that SARS-CoV-2 persists in tissue reservoirs in some patients, continuing to produce viral proteins. Patterson and colleagues reported S1 protein in CD16+ monocytes up to 15 months after infection in post-acute sequelae patients (Patterson et al., 2022). This hypothesis needs no vaccine-specific mechanism and applies to people who were only infected. Imaging work on SARS-CoV-2 cell-to-cell spread suggests one way virus could move between cells in a reservoir without passing through the bloodstream.

Durable expression after vaccination

Vaccine-derived mRNA has been detected in blood up to 28 days after vaccination (Castruita et al., 2023), and germinal centres in lymph nodes have been found to contain vaccine mRNA and spike antigen for up to eight weeks in some cases (Röltgen et al., 2022). Spike-bearing exosomes have been described after vaccination as well (Bansal et al., 2021). How far this extends in humans isn't settled, and questions about where lipid carriers distribute are part of why researchers are testing lipid-free protein nanoparticles for mRNA delivery.

Elevated spike in symptomatic cohorts

A 2025 Yale LISTEN preprint comparing 42 people reporting chronic illness after vaccination with 22 controls found elevated circulating spike protein in the affected group, along with immune profile differences and more frequent Epstein-Barr virus reactivation markers (Bhattacharjee et al., 2025). It's a preprint and cross-sectional, so it describes an association rather than a mechanism.

Beyond these, claims about residual plasmid DNA and genomic integration circulate widely. Integration as a clinical mechanism is not established, the data are contested, and it shouldn't be presented as settled either way. The 2025 JPandS review walkthrough covers how those claims are argued and what evidence sits behind each one.

Why standard protocols often don't move the number

If spike production is genuinely persistent in a given patient, downstream interventions can't switch off the source. That single point explains a lot of frustration.

Fibrinolytic enzymes

Nattokinase, lumbrokinase and serrapeptase act on fibrin and amyloid microclots that have already formed. There's real ex vivo evidence for nattokinase degrading fibrinaloid microclots, which we cover in the nattokinase and lumbrokinase review. They don't bind spike, stop its production, or clear it from tissue.

Spike-binding nutraceutical stacks

Many popular "spike binders" have in vitro affinity data at concentrations hard to reach clinically. None has published evidence of meaningfully lowering circulating spike antigen in humans at recommended dosing. That's a much weaker claim than "this product clears spike."

Anti-inflammatory and antioxidant stacks

NAC, glutathione precursors, curcumin, quercetin and similar agents target inflammatory and oxidative downstream effects. They can produce real symptomatic benefit. They don't clear antigen, and calling them detox stretches the word past usefulness.

What a serious assessment measures

A single number, antibody or antigen, is an input rather than a conclusion. Our comparison of D-dimer versus microclot testing explains why a normal coagulation panel doesn't close the microclot question, and the overview of types of amyloid tests lays out what each amyloid-related test is actually designed to find.

The marketing problem

A meaningful share of "spike detox" products and risk-stratification frameworks sold to patients aren't validated against clinical outcome data. Risk tiers attached to antibody numbers are categories built on immunoassay output, not on studies linking those numbers to patient outcomes.

That doesn't make every compound useless. Some have real biological activity in specific settings. It means the gap between "this molecule showed an effect in a study" and "this stack clears your spike" is large, and much of the marketing lives in that gap.

The simplest question to carry into any sales conversation: what independent clinical evidence shows that this protocol, at this dose, lowers spike antigen rather than antibody, in people in my situation? If the answer is testimonials, you're buying a story.

What's worth doing instead

Move toward antigen-level testing where you can access it, rather than treating an immunoassay number as your primary signal. Track biomarkers that map to mechanism, repeated over time, rather than one titre. Treat what's measurably elevated: if inflammatory markers are up, address that; if amyloid-positive microclots are present, the microclot research literature is where the evidence-based options live; if autoantibody activity is elevated, get a proper rheumatology workup.

Our at-home amyloid test adds one specific observation to that picture. A finger-prick dried blood sample goes to a partner lab in Mexico City, gets stained with Thioflavin T, and is recorded with 6K video microscopy reviewed by AI-assisted detection plus trained human oversight. The Videographic Microscopy Report is yours to share with any provider.

It does not measure spike protein, and it isn't a diagnosis or a medical device. It's laboratory observational data for informational purposes, which is exactly how it should be used: as one input among several, interpreted by a clinician who's looking at your whole picture.

What to read next

For the biology behind why spike fragments might matter to clotting, start with how neutrophil elastase turns spike into amyloid and the follow-up on Spike685 and fibrinolysis resistance. If your symptoms began after vaccination, the review of post-vaccination microclot research covers what the small cohorts have reported. On the delivery side, the work on protein nanoparticles as a lipid-free alternative shows where the field is heading. For practical next steps, the Long COVID survival guide and our free symptom screener are reasonable starting points, and the doctor directory lists clinicians who work in this area.